CALGB Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Adult CIRB - Late Phase Emphasis Closed to Accrual. Pts Still Rcving Intervention Available to Open